1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ptc Therapeutics Hd Inc. has 1 pending office action. The matter is assigned to 1 distinct examiner and 1 distinct art unit, producing a single examination path in the available data.
DIAMOND, ALAN D is the busiest examiner, with 1 pending matter. With no broader portfolio distribution shown, prosecution attention can remain focused on the individual record, its outstanding issues, and the next response or amendment decision.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19395594 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | DIAMOND, ALAN D | 3991 | §112DP | Non-Final OA | — | Pending | Nov 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPtc Therapeutics Hd Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alan D Diamond has the most, with 1 of Ptc Therapeutics Hd Inc.'s pending office actions.
